
Beyond Weight Loss: What the New GLP-1 Aging Data Actually Shows
I read a piece in MIT Technology Review this week (October 6, 2026) that I wanted to share. It covers data that Novo Nordisk and Eli Lilly presented at the
Evidence-based guidance on semaglutide, tirzepatide, and the other GLP-1 medications we prescribe at Mindful Wellness — how they work, what to expect, what they cost, and how we decide which one fits. Written and reviewed by Dr. Vivek Gupta, board certified in Internal Medicine and Obesity Medicine.

I read a piece in MIT Technology Review this week (October 6, 2026) that I wanted to share. It covers data that Novo Nordisk and Eli Lilly presented at the

Phase 2 trial participants on the highest dose lost about a quarter of their body weight, and Phase 3 went higher still. But one in six stopped taking it. Powerful

GLP-1 medications slow the gut on purpose, which is part of how they work and part of why constipation happens. The four categories of laxative, what each one does, and

The first GLP-1 pill for weight management is approved, and orforglipron, CagriSema and retatrutide are behind it. What the trial numbers actually show, side effects included.
BLACK FRIDAYEnds Friday, Dec 5
6 months of medication plus coaching, as low as $217/mo. Many FSA plans expire Dec 31, so use yours on your health instead of losing it.
Starts with a free consultation and a written plan you keep. HSA/FSA eligible. New patients. Paid upfront; monthly figure is the 6-month price divided by 6.